Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. (Q30378897)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Larissa Herkenhoff Haut

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Hildegund C J Ertl

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

13 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

Journal of Leukocyte Biology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

779-793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Prospects of HIV Env modification as an approach to HIV vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

AIDS virus envelope spike structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Antibodies: can they protect against HIV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Roles of HIV-1 Env variable regions in viral neutralization and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Elite control of HIV infection: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Emerging concepts in the immunopathogenesis of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV infection and the gastrointestinal immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

AIDS pathogenesis: a tale of two monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunity in natural SIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Protective immunity induced by live attenuated simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A recoding method to improve the humoral immune response to an HIV DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Characterization and selection of HIV-1 subtype C isolates for use in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Insertion of HIV-1 Genes into Ad4ΔE3 Vector Abrogates Increased Pathogenesis in Cotton Rats Due to E3 Deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

DNA vaccines for HIV: challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

High-level expression of recombinant IgG in the human cell line per.c6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Chimpanzee-origin adenovirus vectors as vaccine carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Post-step modifications for research on HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Activation of virus replication after vaccination of HIV-1-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Effect of influenza vaccination on disease progression among HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Active immunization of rats with a cell-free extract of the erythrocytic parasites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0209094

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines

21 January 2018

1 reference

12 December 2020

Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys.

1 reference

12 December 2020

AIDS vaccine models: challenging challenge viruses

1 reference

12 December 2020

Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques

1 reference

12 December 2020

Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia

1 reference

12 December 2020

Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells

1 reference

12 December 2020

Subversion of host defense mechanisms by adenoviruses.

1 reference

12 December 2020

Adenovirus-Based Expression Vectors and Recombinant Vaccines

1 reference

12 December 2020

Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant

1 reference

12 December 2020

Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease

1 reference

12 December 2020

1 reference

12 December 2020

Use of a Clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine

1 reference

12 December 2020

DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication

1 reference

12 December 2020

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model

1 reference

12 December 2020

1 reference

12 December 2020

HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand

1 reference

12 December 2020

Ten years of highly active antiretroviral therapy for HIV infection

1 reference

12 December 2020

Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice

1 reference

12 December 2020

HIV-1 T-cell vaccines: evaluating the next step

1 reference

12 December 2020

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques

1 reference

12 December 2020

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses

1 reference

12 December 2020

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

1 reference

12 December 2020

Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses

1 reference

12 December 2020

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus

1 reference

12 December 2020

1 reference

12 December 2020

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

1 reference

12 December 2020

Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.

1 reference

12 December 2020

Identifiers

DOI

10.1189/JLB.0209094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19597003%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference